Top 6 Diagnostic Radiopharmaceuticals Shaping Nuclear Medicine

Published: August 2026

Radiopharmaceuticals are agents that combine radioactive isotopes with targeting vectors, forming the foundation of nuclear medicine by enabling molecularly specific, noninvasive imaging and targeted therapy; diagnostic radiopharmaceutical in particular pair positron radionuclides with small molecules and biologics (peptides and antibodies) to visualize physiological processes such as metabolism, receptor expression, perfusion, and inflammation at high sensitivity and quantitative precision. These tracers guide diagnosis, staging and therapy selection across oncology, cardiology, neurology, and infectious / inflammatory diseases. Further, improving diagnostic accuracy, enabling earlier detection and informing personalized treatment decisions while limiting unnecessary invasive procedures and overall radiation exposure.

Recent advances in isotope production, bifunctional chelator chemistry, and radiolabeling techniques, together with novel targets such as PSMA, FAPI, somatostatin receptors and amyloid have broadened tracer repertoires and expanded clinical indications, while hybrid diagnostic imaging platforms (PET / CT, PET / MRI) and quantitative image analysis enhance spatial resolution and diagnostic confidence. Growing integration of diagnostic tracers into theranostic paradigms, companion diagnostics for targeted therapies, and trial enrichment strategies has increased their clinical and commercial value, driving higher adoption among clinicians and imaging centers.

As oncology precision medicine accelerates, demand for specific, reliable diagnostic radiopharmaceuticals is rising, presenting substantial opportunities for radiochemistry innovators, isotope suppliers, diagnostic imaging equipment manufacturers, and healthcare systems to improve patient pathways, optimize resource utilization, and advance outcome-driven care.

Roots Analysis has conducted an exhaustive study on Radiopharmaceuticals Market featuring the current market landscape and future opportunities for the companies engaged in healthcare, over a span of next 14 years.

Top 6 Diagnostic Radiopharmaceuticals

Choletec®
MyoviewTM
CeretecTM
Neurolite®
Cardiolite®
Netspot®

The figure below highlights the diagnostic radiopharmaceutical:

Top 6 Diagnostic to Watch Radiopharmaceuticals

Interested in exploring all 600+ radiopharmaceuticals, along with their recent initiatives?

Discover Below the Details on Diagnostic Radiopharmaceutical

Let us dive deep into the details of the diagnostic radiopharmaceutical. It is essential to note that the selection of diagnostic radiopharmaceutical can differ substantially according to the defined criteria.

1. Choletec®

The section provides information on the various parameters, with details on list of developer, format of radiopharmaceutical, type of radioisotope, type of emitter, route of administration, and target indication.

Developer: Bracco
Format of Radiopharmaceutical: Kits
Type of Radioisotope: Technetium-99m
Type of Emitter: Gamma
Route of Administration: Intravenous
Target Indication: Hepatobiliary Disease

To know more about Choletec® and other diagnostic radiopharmaceutical, access full report.

2. MyoviewTM

Developer: GE Healthcare
Format of Radiopharmaceutical: Kits
Type of Radioisotope: Technetium-99m
Type of Emitter: Gamma
Route of Administration: Intravenous
Target Indication: Coronary Artery Disease

To know more about MyoviewTM and other diagnostic radiopharmaceutical, access full report.

3. CeretecTM

Developer: GE Healthcare
Format of Radiopharmaceutical: Kits
Type of Radioisotope: Technetium-99m
Type of Emitter: Gamma
Route of Administration: Intravenous
Target Indication: Intraabdominal Infection, Inflammatory Bowel Disease and Stroke

To know more about CeretecTM and other diagnostic radiopharmaceutical, access full report.

4. Neurolite®

Developer: Lantheus
Format of Radiopharmaceutical: Kits
Type of Radioisotope: Technetium-99m
Type of Emitter: Gamma
Route of Administration: Intravenous
Target Indication: Stroke

To know more about Neurolite® and other diagnostic radiopharmaceutical, access full report.

5. Cardiolite®

Developer: Lantheus
Format of Radiopharmaceutical: Kits
Type of Radioisotope: Technetium-99m
Type of Emitter: Gamma
Route of Administration: Intravenous
Target Indication: Coronary Artery Disease

To know more about Cardiolite® and other diagnostic radiopharmaceutical, access full report.

6. Netspot®

Developer: Siemens Healthineers
Format of Radiopharmaceutical: Kits
Type of Radioisotope: Gallium-68
Type of Emitter: Beta, Gamma
Route of Administration: Intravenous
Target Indication: Neuroendocrine Tumor

To know more about Netspot® and other diagnostic radiopharmaceutical, access full report.

What About Other Diagnostic Radiopharmaceutical Around the World?

The above article features the diagnostic radiopharmaceutical selected from a pool of more than 600 radiopharmaceuticals that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources: